Format

Send to

Choose Destination
Europace. 2016 Jan;18(1):146-50. doi: 10.1093/europace/euw003.

The use of wearable cardioverter-defibrillators in Europe: results of the European Heart Rhythm Association survey.

Author information

1
Department of Cardiology, Congenital Heart Disease and Electrotherapy, Silesian Medical University, Silesian Center for Heart Disease, Curie-Skłodowskiej 9, Zabrze 41-800, Poland radle@poczta.onet.pl.
2
School of Medicine, Belgrade University, Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia.
3
Department of Cardiology, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
4
Cardiology Department, Ramón y Cajal Hospital, Madrid 28034, Spain.
5
Department of Cardiology, Institution of Medical Science, Uppsala University, Uppsala 75185, Sweden.
6
Department of Electrophysiology, Heart Center Leipzig, Leipzig, Germany.

Abstract

The aim of this European Heart Rhythm Association (EHRA) survey was to collect data on the use of wearable cardioverter-defibrillators (WCDs) among members of the EHRA electrophysiology research network. Of the 50 responding centres, 23 (47%) reported WCD use. Devices were fully reimbursed in 17 (43.6%) of 39 respondents, and partially reimbursed in 3 centres (7.7%). Eleven out of 20 centres (55%) reported acceptable patients' compliance (WCD worn for >90% of time). The most common indications for WCD (8 out of 10 centres; 80%) were covering the period until re-implantation of ICD explanted due to infection, in patients with left ventricular impairment due to myocarditis or recent myocardial infarction and those awaiting heart transplantation. Patient life expectancy of <12 months and poor compliance were the most commonly reported contraindications for WCD (24 of 46 centres, 52.2%). The major problems encountered by physicians managing patients with WCD were costs (8 of 18 centres, 44.4%), non-compliance, and incorrect use of WCD. Four of 17 centres (23.5%) reported inappropriate WCD activations in <5% of patients. The first shock success rate in terminating ventricular arrhythmias was 95-100% in 6 of 15 centres (40%), 85-95% in 4 (26.7%), 75-85% in 2 (13.3%), and <75% in 3 centres (20%). The survey has shown that the use of WCD in Europe is still restricted and depends on reimbursement. Patients' compliance remains low. Heterogeneity of indications for WCD among centres underscores the need for further research and a better definition of indications for WCD in specific patient groups.

KEYWORDS:

EHRA survey; EP wire; Heart failure; Implantable cardioverter-defibrillator; Prevention; Sudden cardiac death; Ventricular arrhythmias; Wearable cardioverter-defibrillator

PMID:
26842735
DOI:
10.1093/europace/euw003
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for Norwegian BIBSYS system
Loading ...
Support Center